MK5684-004

A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)

Enquire

Trial overview

Disease

Prostate cancer

Topic

OMAHA-2a

Sponsor

MSD

Description

Study details

For detailed information on this trial, please click here

Trial status

Due to open May 24

Location

Oxford Windsor

Priniciple Investigator

Dr Nicola Dallas

MBChB, MRCP, FRCR

Clinical Oncologist

Windsor +1

Prof Andrew Protheroe

MBBS, FRCP, PhD

Medical oncologist

Milton Keynes +1